Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

122.98 -0.20 (-0.16%)
Streaming Delayed Price Updated: 12:53 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
69 70 Next >
News headline image
The Great Rebalancing: As Consumer Confidence Falters, Investors Retreat to the Safety of Large-Cap Value
As the curtain closes on 2025, the exuberant "risk-on" sentiment that defined the early years of the artificial intelligence boom has been replaced by a somber, calculated retreat. On this final day of... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
What&#39;s Driving the Market Sentiment Around Gilead Sciences Inc? ↗
 
Via Benzinga
News headline image
Stock Index Futures Slip in Weak End to a Banner Year
March S&P 500 E-Mini futures (ESH26) are down -0.20%, and March Nasdaq 100 E-Mini futures (NQH26) are down -0.32% this morning, pointing to a weak start on Wall Street in the final trading session of... 
Via Barchart.com
Topics Bonds Government Stocks
Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs ↗
Via Stocktwits
News headline image
Discover which S&P500 stocks are making waves on Tuesday. ↗
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
News headline image
GILEAD SCIENCES INC (NASDAQ:GILD) Shows High Technical and Setup Ratings for a Potential Breakout ↗
Gilead Sciences (GILD) shows strong technicals and a high-quality setup, suggesting a potential breakout from a tight trading range for chart-focused investors. 
Via Chartmill
News headline image
Jobless Claims Unexpectedly Fall For Second Consecutive Week ↗
According to data released by the U.S. Department of Labor on Wednesday, jobless claims fell by 10,000 to 214,000 in the week ended December 20. 
Via Stocktwits
Topics Stocks
News headline image
Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million ↗
Gilead agreed to acquire Repare's RP-3467 cancer drug for up to $30 million, boosting Repare's cash and expected shareholder payout. 
Via Benzinga
News headline image
RPTX Stock Soars Pre-Market After Gilead Agrees To Acquire Investigational Cancer Drug ↗
Repare stated that Gilead has agreed to acquire polymerase theta (Polθ) ATPase inhibitor, RP-3467, for a total consideration of $30 million. 
Via Stocktwits
Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗
Via Stocktwits
Topics Government
News headline image
These S&P500 stocks are moving in today's session ↗
Stay updated with the movements of the S&P500 index in the middle of the day on Tuesday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
News headline image
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes ↗
Gilead licensed Assembly Bio's long-acting HSV drugs after Phase 1b data showed antiviral activity and weekly oral dosing potential. 
Via Benzinga
News headline image
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal ↗
Trump and nine major pharmaceutical companies struck deals to lower drug prices for cash payers and Medicaid, with over $150 billion pledged for U.S. R&D and manufacturing. 
Via Benzinga
Topics Government
News headline image
Why Gilead Sciences (GILD) Stock Is Up Today
Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 3.3% in the afternoon session after the stock's positive momentum continued as the company announced a series of positive... 
Via StockStory
Topics Earnings
News headline image
Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗
The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief. 
Via Stocktwits
Topics Government World Trade
News headline image
Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump ↗
Dow Jones stock Merck forged a Most Favored Nation agreement with the Trump administration on Friday. 
Via Investor's Business Daily
Topics Government Stocks
News headline image
Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Inc. (NASDAQ:GILD): A High-Quality Dividend Stock for Reliable Income ↗
Gilead Sciences (GILD) offers a reliable 2.56% dividend yield, backed by strong profitability, a debt-free balance sheet, and a decade of consistent payouts. 
Via Chartmill
News headline image
AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report ↗
This comes after President Donald Trump urged drugmakers in July to lower drug prices for the U.S. government’s Medicaid program. 
Via Stocktwits
Topics Economy Government
News headline image
Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗
The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing. 
Via Stocktwits
Topics Government World Trade
News headline image
Here&#39;s How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗
 
Via Benzinga
News headline image
Gilead&#39;s Experimental Combo Tablet For HIV Treatment Hits Primary Goal ↗
Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial. 
Via Benzinga
News headline image
3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains ↗
Via MarketBeat
News headline image
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak ↗
Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead-partnered cancer regimen failed. 
Via Investor's Business Daily
News headline image
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Gilead Sciences Inc. (NASDAQ:GILD) Presents a Compelling Profile for Value Investors ↗
Gilead Sciences (GILD) presents a strong value investing case, trading at a discount to its industry with high profitability, no debt, and improving earnings growth forecasts. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
69 70 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.